高风险前列腺癌中度大分割放疗联合选择性盆腔淋巴结照射的Meta分析
该Meta分析纳入18项研究共1745例接受中度大分割放疗联合选择性盆腔淋巴结照射的高风险前列腺癌患者,中位随访61个月。5年生化无复发生存率为90%,晚期≥2级胃肠道和泌尿生殖系统毒性发生率分别为6.7%和11.3%,严重毒性罕见。
要点
- 5年生化无复发生存率为90%(95%CI 88%-94%),7年和10年分别为83%和78%
- 5年前列腺癌特异性生存率98%,总生存率93%
- 晚期≥2级胃肠道和泌尿生殖系统毒性发生率分别为6.7%和11.3%,3-5级毒性罕见
核心结论
- 选择性盆腔淋巴结照射联合中度大分割放疗在长期随访中提供满意的生化无复发生存率,泌尿生殖系统和胃肠道严重毒性发生率低,盆腔和局部失败率极低。
研究设计与样本
- Meta分析,检索MEDLINE、Embase、Cochrane Library及截至2021年10月的年会论文集,遵循PRISMA和MOOSE指南,纳入18项研究共1745例接受选择性盆腔淋巴结照射联合中度大分割放疗的患者,中位随访61个月。
主要发现
- 5年、7年、10年生化无复发生存率分别为90%(95%CI 88%-94%)、83%(95%CI 78%-91%)、78%(95%CI 68%-88%)。
- 5年前列腺癌特异性生存率98%(95%CI 97%-99%),无病生存率88.7%(95%CI 85%-93%),无远处转移生存率91.2%(95%CI 88%-92%),总生存率93%(95%CI 90%-96%)。
- 局部、盆腔和远处复发率分别为0.38%(95%CI 0%-2%)、0.13%(95%CI 0%-1.5%)和7.35%(95%CI 2%-12%)。
- 晚期≥2级胃肠道和泌尿生殖系统毒性发生率分别为6.7%(95%CI 4%-9%)和11.3%(95%CI 7.6%-15%),存在异质性,但3-5级毒性罕见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite several advances in planning and delivery of radiation therapy (RT) for prostate cancer, the role of elective pelvic nodal irradiation (EPNI) remains controversial for high-risk disease. We performed a meta-analysis to evaluate the outcomes of patients treated with moderate hypofractionated RT (MHF-RT) with EPNI using modern RT techniques. METHODS AND MATERIALS: Eligible studies were identified on MEDLINE, Embase, the Cochrane Library, and proceedings of annual meetings through October 2021. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) and MOOSE (Meta-analyses of Observational Studies in Epidemiology) guidelines. A metaregression analysis was performed to assess a possible correlation between selected variables and outcomes. A P value <.05 was considered significant. RESULTS: Eighteen studies with a total of 1745 patients (median follow-up, 61 months) treated with EPNI using MHF-RT were included. The biochemical relapse-free survival at 5, 7, and 10 years was 90% (95% confidence interval [CI], 88%-94%), 83% (95% CI, 78%-91%), and 78% (95% CI, 68%-88%). The 5-year prostate cancer-specific survival, disease-free survival, distant metastases-free survival, and overall survival were 98% (95% CI, 97%-99%), 88.7% (95% CI, 85%-93%), 91.2% (95% CI, 88%-92%), and 93% (95% CI, 90%-96%), respectively. The rates of local, pelvic, and distant recurrence were 0.38% (95% CI, 0%-2%), 0.13% (95% CI, 0%-1.5%), and 7.35% (95% CI, 2%-12%), respectively. The rate of late grade ≥2 gastrointestinal and genitourinary toxic effects were 6.7% (95% CI, 4%-9%) and 11.3% (95% CI, 7.6%-15%), with heterogeneity, but with rare cases of grade 3 to 5 toxic effects. CONCLUSIONS: EPNI with concomitant MHF-RT provides satisfactory biochemical relapse-free survival in long-term follow-up, with low rates of genitourinary and gastrointestinal severe toxic effects and minimal pelvic and local failure.
引用
- Viani GA, Gouveia AG, Moraes FY, et al. Meta-analysis of Elective Pelvic Nodal Irradiation Using Moderate Hypofractionation for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35430317. doi:10.1016/j.ijrobp.2022.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。